HMGB1 expression levels correlate with response to immunotherapy in non-small cell lung cancer. González–Cao M, De Marchi P, Cai X, et al. – Dovepress, 2024.

PMID: 38741920 | DOI: 10.2147/LCTT.S455034

Cardiology and oncology – a meeting of giants. Dutra JP, De Marchi P, Scarlatelli Macedo AV, et al. – Revista da Associação Médica Brasileira, 2024.

PMID: 38865534 | DOI: 10.1590/1806–9282.2024S114

Fifteen years of precision medicine in the lung cancer management: perspectives and challenges. Ferreira CG, De Marchi P, Veloso GG, et al. – Medical Research Archives, 2024.

DOI: 10.18103/mra.v12i2.5169

Gene expression profiles (GEPs) of immuno–oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC. Leal LF, De Marchi P, da Silva LS, et al. – Translational Oncology, 2023.

PMID: 37918166 | DOI: 10.1016/j.tranon.2023.101818

EGFR mutation detection in Brazilian patients with non-small-cell lung cancer: lessons from real-world data scenario of molecular testing. Montella T, De Marchi P, Zalis M, et al. – JCO Global Oncology, 2023.

PMID: 37769218 | DOI: 10.1200/GO.22.00426

Hypofractionated versus normofractionated accelerated radiation therapy with or without cisplatin for locally advanced head and neck squamous cell carcinoma (HYPNO): a randomized, open-label, Phase 3, noninferiority trial. Søren M Bentzen, De Marchi P, Tejpal Gupta, et al. – International Journal of Radiation Oncology - Biology - Physics, 2026.

PMID: 41711624 | DOI: 10.1016/j.ijrobp.2025.12.056

Feasibility of a ctDNA multigenic panel for non-small-cell lung cancer early detection and disease surveillance. Giovanna Maria Stanfoca Casagrande, De Marchi P, Marcela de Oliveira Silva, et al. – Molecular Oncology, 2025.

PMID: 41071680 | DOI: 10.1002/1878–0261.70131

Optimizing muscle mass and function in advanced lung cancer patients: randomized, double-blind, placebo-controlled trial protocol using high eicosapentaenoic acid and PROtein (HEPRO) to modulate epigenetics, reduce toxicity and improve gut microbiota. Imanuely Borchardt, De Marchi P, Carla Prado, et al. – PeerJ, 2025.

PMID: 40487055 | DOI: 10.7717/peerj.19506

Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA. D P Carbone, De Marchi P, T–E Ciuleanu, et al. – ESMO Open, 2025.

PMID: 40446626 | DOI: 10.1016/j.esmoop.2025.105123

Preoperative neoadjuvant chemotherapy or immunotherapy in head and neck cancer: a systematic review and meta-analysis of surgical risk and pathologic response. Caique Mariano Pedroso, De Marchi P, Mariana de Pauli Paglioni, et al. – Critical Reviews in Oncology/Hematology, 2025.

PMID: 40348212 | DOI: 10.1016/j.critrevonc.2025.104742

HOXA9 methylation is not associated with survival in Brazilian patients with lung adenocarcinoma. Anna Luiza Silva Almeida Vicente, De Marchi P, Fabiana Aparecida de Souza Santos, et al. – Clinical Epigenetics, 2025.

PMID: 39962529 | DOI: 10.1186/s13148–025–01831–1

Real-world study on implementation of genomic tests for advanced lung adenocarcinoma in Brazil. Rodrigo Dienstmann, De Marchi P, Leonard M da Silva, et al. – JCO Global Oncology, 2024.

PMID: 39571128 | DOI: 10.1200/GO–24–00354

Molecular profile of driver genes in lung adenocarcinomas of Brazilian patients who have never smoked: implications for targeted therapies. Rodrigo de Oliveira Cavagna, De Marchi P, Flávia Escremim de Paula, et al. – Oncologist. 2024.

PMID: 38944844 | DOI: 10.1093/oncolo/oyae129

Latin American Consensus on the treatment of head and neck cancer. Leandro Luongo Matos, De Marchi P, Luiz Paulo Kowalski, et al. – JCO Global Oncology, 2024.

PMID: 38603656 | DOI: 10.1200/GO.23.00343

Canakinumab as adjuvant therapy in patients with completely resected non-small-cell lung cancer: results from the CANOPY-a double-blind, randomized clinical trial. Edward B Garon, De Marchi P, Shun Lu, et al. – Journal of Clinical Oncology, 2024.

PMID: 37788412 | DOI: 10.1200/JCO.23.00910

Brazilian Expert Consensus for NTRK gene fusion testing in solid tumors. Mariana Petaccia de Macedo, De Marchi P, Ellen Caroline Toledo Nascimento, et al. – Journal of Clinical Pathology, 2023.

PMID: 37719804 | DOI: 10.1177/2632010X231197080

Polarization of melatonin-modulated Colostrum macrophages in the presence of breast tumor cell lines. Kenia Maria Rezende Silva , De Marchi P, Danielle Cristina Honório França, et al. – International Journal of Molecular Sciences, 2023.

PMID: 37569777 | DOI: 10.3390/ijms241512400

Disruptive and truncating TP53 mutations are associated with African–ancestry and worse prognosis in Brazilian patients with lung adenocarcinoma. Rodrigo de Oliveira Cavagna, De Marchi P, Icaro Alves Pinto, et al. – Pathobiology, 2023.

PMID: 37031678 | DOI: 10.1159/000530587

ERBB2 exon 20 insertions are rare in Brazilian non–small cell lung cancer. Rodrigo de Oliveira Cavagna, De Marchi P, Beatriz Garbe Zaniolo, et al.– Thoracic Cancer, 2022.

PMID: 36251951 | DOI: 10.1111/1759–7714.14605

Discrepancies between the cost of advanced lung cancer treatment and how much is reimbursed by the Brazilian public healthcare system. Marina Kelner , De Marchi P, Bruna Carvalho da Silva, et al. – Value in Health Regional Issues, 2023.

PMID: 36162194 | DOI: 10.1016/j.vhri.2022.08.004

EGFR mutations and PD–L1 expression in early-stage non-small cell lung cancer: a real-world data from a single center in Brazil. Icaro Alves Pinto, De Marchi P, Rodrigo de Oliveira Cavagna, et al. – The Oncologist, 2022.

PMID: 36099421 | DOI: 10.1093/oncolo/oyac167

Non-small-cell lung cancer with CNS metastasis: disparities from a real-world analysis (GBOT–LACOG 0417). Juliano Cé Coelho, De Marchi P, Giselle de Souza Carvalho, et al. – JCO Global Oncology, 2022.

PMID: 35467932 | DOI: 10.1200/GO.21.00333

Corrigendum to 'first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non–small cell lung cancer: CheckMate 9LA 2–year update'. M Reck, De Marchi P, T–E Ciuleanu, et al. – ESMO Open. 2021.

PMID: 34864501 | DOI: 10.1016/j.esmoop.2021.100345

Microsatellite instability is rare in the admixed Brazilian population of non-small cell lung cancer: a cohort of 526 cases. Gustavo Noriz Berardinelli, Pedro De Marchi, Rodrigo de Oliveira Cavagna, et al. – Pathobiology, 2022

PMID: 34781284 | DOI: 10.1159/000520023

First–line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2–year update. M Reck 1, De Marchi P, T-E Ciuleanu, et al. – ESMO Open, 2022.

PMID: 34607285 | DOI: 10.1016/j.esmoop.2021.100273

Exergame training-induced neuroplasticity and cognitive improvement in institutionalized older adults: a preliminary investigation. M Monteblanco Cavalcante, De Marchi P, I Fraga, et al. – Physiology and Behavior, 2021.

PMID: 34509470 | DOI: 10.1016/j.physbeh.2021.113589

Evaluation of acetylation and methylation in oral rinse of patients with head and neck cancer history exposed to valproic acid. Ricardo Ribeiro Gama , De Marchi P, Lidia Maria Rebolho Batista Arantes, et al.– Scientific Reports, 2021.

PMID: 34385507 DOI: 10.1038/s41598-021-95792-2

DNA methylation markers from negative surgical margins can predict recurrence of oral squamous cell carcinoma. Bruna Pereira Sorroche, De Marchi P, Fazlur Rahman Talukdar, et al. – Cancers, 2021.

PMID: 34207933 | DOI: 10.3390/cancers13122915

Frequency of KRAS p.Gly12Cys mutation in Brazilian patients with lung cancer. Rodrigo Cavagna, De Marchi P, Flávia Escremim de Paula, et al. – JCO Global Oncology, 2021.

PMID: 33956502 | DOI: 10.1200/GO.20.00615

PD–L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC). Leticia Ferro Leal, Pedro De Marchi, Vinicius Duval da Silva, et al.. – Journal of Clinical Pathology, 2021.

PMID: 33589532 | DOI: 10.1136/jclinpath–2020–206832

Simultaneous analysis of ALK, RET, and ROS1 gene fusions by NanoString in Brazilian lung adenocarcinoma patients. Lázaro Antonio Campanha Novaes, De Marchi P, Luciane Sussuchi da Silva, et al. – Translational Lung Cancer Research, 2021.

PMID: 33569313 | DOI: 10.21037/tlcr–20–740

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open–label, phase 3 trial. Luis Paz–Ares, De Marchi P, Tudor–Eliade Ciuleanu, et al. – The Lancet Oncology, 2021.

PMID: 33476593 | DOI: 10.1016/S1470–2045(20)30641–0

Determinants of COVID–19 mortality in patients with cancer from a community oncology practice in Brazil. Bruno L Ferrari, De Marchi P, Carlos Gil Ferreira, et al. – JCO Global Oncology, 2021.

PMID: 33434066 | DOI: 10.1200/GO.20.00444

Dealing with lung cancer in the COVID–19 scenario (a review). Veronica Aran, Pedro De Marchi, Mauro Zamboni, et al. – Molecular and Clinical Oncology, 2021.

PMID: 33414908 | DOI: 10.3892/mco.2020.2189

Using co-segregation and loss of heterozygosity analysis to define the pathogenicity of unclassified variants in hereditary breast cancer patients. Rebeca Silveira Grasel, De Marchi P, Paula Silva Felicio, et al. – Frontiers in Oncology, 2021.

PMID: 33134171 | DOI: 10.3389/fonc.2020.571330

Real-world molecular testing and treatment patterns in Brazilian patients with newly diagnosed locally advanced or metastatic NSCLC. Eduardo Cronemberger, De Marchi P, Clarissa Baldotto, et al. – Clinics (São Paulo), 2020.

PMID: 33084767 | DOI: 10.6061/clinics/2020/e1777

EGF+61 A>G polymorphism does not predict response to first-generation EGFR tyrosine kinase inhibitors in lung cancer patients. Leticia F Leal, De Marchi P, Ana C Laus, et al. – Thoracic Cancer, 2020.

PMID: 32881389 | DOI: 10.1111/1759–7714.13628

Feasibility of methylated ctDNA detection in plasma samples of oropharyngeal squamous cell carcinoma patients. Lais Machado de Jesus, De Marchi P, Mariana Bisarro Dos Reis, et al. – Head Neck, 2020.

PMID: 32687251 | DOI: 10.1002/hed.26385

Impact of genetic variants in clinical outcome of a cohort of patients with oropharyngeal squamous cell carcinoma. Ana Carolina de Carvalho, De Marchi P, Sandra Perdomo, et al. – Science Reports, 2020.

PMID: 32561788 | DOI: 10.1038/s41598–020–66741–z

Real-world prevalence of PD–L1 expression among tumor samples from patients with non-small-cell lung cancer. Ana C Z Gelatti, De Marchi P, Vladmir C Cordeiro de Lima, et al. – Clinical Lung Cancer, 2020.

PMID: 32389509 | DOI: 10.1016/j.cllc.2020.04.007

The role of single–nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer. Matias E Melendez, Pedro De Marchi, Ana C Laus, et al. – Oral Oncology, 2019.

PMID: 31539757 | DOI: 10.1016/j.oraloncology.2019.09.013

Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations. Letícia Ferro Leal, De Marchi P, Flávia Escremim de Paula, et al. – Science Rep, 2019.

PMID: 30824880 | DOI: 10.1038/s41598–019–39965–x

EGF+61 A>G polymorphism is not associated with lung cancer risk in the Brazilian population. Ana Carolina Laus, De Marchi P, Flavia Escremim de Paula, et al. – Molecular Biology Reports, 2019.

PMID: 30783937 | DOI: 10.1007/s11033–019–04702–0

Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma. Alexandre Arthur Jacinto, De Marchi P, Eronides Salustiano Batalha Filho, et al. – BMC Cancer, 2018.

PMID: 30352576 | DOI: 10.1186/s12885–018–4893–5

Detection of ALK fusion transcripts in FFPE lung cancer samples by NanoString technology. Adriane F Evangelista, De Marchi P, Maicon F Zanon, et al. – BMC Pulmonary Medicine, 2017.

PMID: 28549458 | DOI: 10.1186/s12890–017–0428–0

MiR–21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol. Lidia Maria Rebolho Batista Arantes, De Marchi P, Ana Carolina Laus – Oncotarget, 2017.

PMID: 28039483 | DOI: 10.18632/oncotarget.14253

Criteria for eligibility to cisplatin in the curative treatment of head and neck cancer: consensus opinion from a panel of experts. Gilberto de Castro Jr, De Marchi P, Gustavo V Alves, et al. – Critical Reviews in Oncology/Hematology, 2018.

PMID: 30293703 | DOI: 10.1016/j.critrevonc.2018.08.009

Lung cancer in Brazil. Luiz Henrique Araujo, De Marchi P, Clarissa Baldotto, et al. – Jornal Brasileiro de Pneumologia. 2018

DOI: 10.1590/S1806–37562017000000135

Impact of AferBio® on quality of life and chemotherapy toxicity in advanced lung cancer patients (AFERBIO study): protocol study for a phase II randomized controlled trial. Daniel D'Almeida Preto , De Marchi P, Mariana Toledo Baston, et al- BMC Cancer, 2019.

PMID: 31023257 | DOI: 10.1186/s12885-019-5599-z

Efficacy of osimertinib in advanced T790M-positive NSCLC after progression to prior EGFR-TKI: real world data from a Brazilian cohort. Luiz Henrique Araujo, De Marchi P, Gilberto de Castro Jr, et al. - Brazilian Journal of Oncology, 2020.

DOI: 10.5935/2526-8732.20200005

Monitoring non-small cell lung cancer progression and treatment response through hyaluronic acid in sputum. J Chinoca, De Marchi P, D S Andrade, et al. - Brazilian Journal of Medical and Biological Research, 2021.

PMID: 35320334 | DOI: 10.1590/1414-431X2021e11513

ORCID:Pedro De Marchi (0000–0001–5259–0215)

Prognostic significance of peritoneal metastasis from colorectal cancer treated with first-line triplet chemotherapy. Abdulrahman Alghabban, Shouki Bazarbashi, Mohamed Aseafan et al. – World J Clin Cases, 2022.

PMID: 35434075 | DOI: 10.12998/wjcc.v10.i8.2429

Outcomes and prognostic factors of metastatic gastric cancer: a single-center experience. Mohamed Aseafan, Shouki Bazarbashi, Ahmed Mostafa Gad, et al. – Cureus, 2022.

PMID: 36043200 | DOI: 10.7759/cureus.28426

Nationwide prevalence of hepatocellular carcinoma in Saudi Arabia: a population-based analysis for 2021. De Vol EB, Bazarbashi S, Aseafan M, et al. – Journal of Hepatocellular Carcinoma, 2025.

PMID: 41487559 | DOI: 10.2147/JHC.S576090

Docetaxel versus androgen receptor pathway inhibitors as first-line therapy for metastatic castration-resistant prostate cancer after doublet therapy: a multicenter retrospective study from Saudi Arabia. Abdelmotal AS, Bazarbashi S, Arabi T, et al. – BMC Urology, 2025.

PMID: 41430171 | DOI: 10.1186/s12894–025–02019–8

Neoadjuvant chemoradiotherapy for locally advanced rectal cancer using infusional gemcitabine: immune cell infiltration analysis and updated survival. AlManea H, Bazarbashi S, Aljubran A, et al. – Cancer Medicine, 2025.

PMID: 35146939 | DOI: 10.1002/cam4.4590

Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care center. Mohamed Aseafan, Shouki Bazarbashi, Tasnim Elgazzar, et al. – BMC Endocrine Disorders, 2023.

PMID: 37029347 | DOI: 10.1186/s12902–023–01326–1

Treatment outcome and chemoresistance-related factors of low-risk gestational trophoblastic neoplasia: results from a tertiary care center in Saudi Arabia. Bader Alshamsan, Shouki Bazarbashi, Inaam Ahmed Ibrahim, et al. – JCO Global Oncology, 2025.

PMID: 41397193 | DOI: 10.1200/GO–25–00172

Real-world clinical outcome of unresectable locally advanced & de–novo metastatic pancreatic ductal adenocarcinoma: a multicenter retrospective study. Mohamed Aseafan, Shouki Bazarbashi, Emad Tashkandi, et al. – BioMed Central Cancer, 2025.

PMID: 39754118 | DOI: 10.1186/s12885–024–13386–0

The role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: review by Middle East and North African Experts. Heba Mohamed El Zawahry, Shouki Bazarbashi, Tarek Owaidah, et al. – Journal of Blood Medicine, 2024.

PMID: 38686358 | DOI: 10.2147/JBM.S411520

Efficacy of chemotherapy rechallenge versus regorafenib or trifluridine/tipiracil in third-line setting of metastatic colorectal cancer: a multicenter retrospective comparative study. Mohamed Aseafan, Shouki Bazarbashi, Radwan Alkhatib, et al. – JCO Global Oncology, 2024.

PMID: 38484194 | DOI: 10.1200/GO.23.00461

Treatment patterns and recommendations for improving the management of hepatocellular carcinoma in Saudi Arabia. Ashwaq Alolyan, Shouki Bazarbashi, Kanan Alshammari, et al. – The Journal of Hepatocellular Carcinoma, 2024

PMID: 38385059 | DOI: 10.2147/JHC.S442842

Phase II trial of FOLFIRINOX in advanced biliary tract cancer. Mohammed Aseafan, Shouki Bazarbashi Mahmoud A., et al. – Cureus, 2024.

PMID: 38380191 | DOI: 10.7759/cureus.52656

Characteristics and outcomes of small bowel adenocarcinoma: 14 years of experience at a single tertiary hospital in Saudi Arabia. Bader Alshamsan, Shouki Bazarbashi, Ahmed Badran, et al. – Molecular and Clinical Oncology, 2023.

PMID: 36798464 | DOI: 10.3892/mco.2023.2613

The Saudi Consensus for the Management of cancer-associated thromboembolism: a modified Delphi-based study. Mohammed Alsheef, Shouki Bazarbashi, Ashraf Warsi, et al. – TH Open, 2023.

PMID: 36751300 | DOI: 10.1055/s–0042–1758856

Combining sunitinib and bevacizumab for the management of advanced renal cell carcinoma: a phase I/II trial. Ahmed Alzahrani, Shouki Bazarbashi, Ali Aljubran, et al. – Oncologist, 2023.

PMID: 36648325 | DOI: 10.1093/oncolo/oyac261

Retrospective evaluation of the impact of dose escalation using pre-operative simultaneous integrated boost Volumetric Modulated Arc Therapy on the outcome of locally advanced rectal cancer patients. Ahmed Elashwah, Shouki Bazarbashi, Abdullah Alsuhaibani, et al. – The Journal of Gastrointestinal Oncology, 2023.

PMID: 36525233 | DOI: 10.1007/s12029–022–00882–4

Management of metastatic castration–resistant prostate cancer in Middle East African countries: challenges and strategic recommendations. Abdullah Alsharm, Shouki Bazarbashi, Alaa Meshref, et al. – Urology Annals, 2022.

PMID: 36505997 | DOI: 10.4103/ua.ua_148_21

Outcomes of patients with metastatic colorectal cancer treated with trifluridine/tipiracil beyond the second line: a multicenter retrospective study from Saudi Arabia. Mohammed Alghamdi, Shouki Bazarbashi, Mohamed Aseafan, et al. – Journal of Oncology, 2022.

PMID: 36147443 | DOI: 10.1155/2022/3796783

Combined prophylactic hyperthermic intraperitoneal chemotherapy and intraoperative radiotherapy for localized gastroesophageal junction and gastric cancer: a comparative nonrandomized study. Ahmed Badran, Shouki Bazarbashi, Ahmed Mostafa Gad, et al. – Annals of Surgical Oncology, 2023.

PMID: 36042103 | DOI: 10.1245/s10434–022–12467–3

Methodological approaches to cost-effectiveness analysis in Saudi Arabia: what can we learn? A systematic review. Fatma Maraiki, Shouki Bazarbashi, Paul Scuffham, et al. – MDM Policy & Practice, 2022.

PMID: 35647291 | DOI: 10.1177/23814683221086869

Thromboembolic events burden in patients with solid tumors and their predisposing factors. Mohamed Aseafan, Shouki Bazarbashi, Turkiah Alkhaldi, et al. – Cureus Journal of Medical Science, 2022.

PMID: 35386484 | DOI: 10.7759/cureus.23624

Population–based survival for cancer patients in Saudi Arabia for the years 2005–2009. Edward Devol, Shouki Bazarbashi, Mahmoud AlAhwal, et al. – Scientific Reports, 2024.

PMID: 34997176 | DOI: 10.1038/s41598–021–04374–6

Classification of early–stage colon cancer with Immunoscore®: clinical evidence and case studies. Suayib Yalcin, Shouki Bazarbashi, Philip A Philip, et al. – Future Oncology, 2022.

PMID: 34904905 | DOI: 10.2217/fon–2021–0712

A narrative review of implementing precision oncology in metastatic castration-resistant prostate cancer in emerging countries. Wen–Pin Su, Shouki Bazarbashi, Siew W Wong, et al. – Oncology and Therapy, 2021.

PMID: 34236692 | DOI: 10.1007/s40487–021–00160–6

Cancer management in Saudi Arabia: recommendations by the Saudi Oncology Health economics expert group (SHARP). Nora Alkhudair, Shouki Bazarbashi, Majed Alshamrani, et al. – Saudi Pharmaceutical Journal, 2021.

PMID: 33679175 | DOI: 10.1016/j.jsps.2020.12.005

Elicitation of health utilities in oncology in the Kingdom of Saudi Arabia. Michael Iskedjian, Shouki Bazarbashi, Edward De Vol, et al. – JCO Global Oncology, 2020.

PMID: 33108230 | DOI: 10.1200/GO.20.00234

The clinical significance of routine risk categorization in metastatic renal cell carcinoma and its impact on treatment decision-making: a systematic review. Abdullah Alsharm, Shouki Bazarbashi, Faisal Azam, et al. – Future Oncology, 2020.

PMID: 32869660 | DOI: 10.2217/fon–2020–0500

Clinical recommendations in the management of advanced prostate cancer: international gastrointestinal, liver and uro-oncology (IGILUC 2019) experts. Hesham Elghazaly, Shouki Bazarbashi, Nicolas Mottet, et al.. – World Journal of Urology, 2021.

PMID: 32643031

Survival benefit of surgical resection after first–line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer. Mahmoud A Elshenawy, Shouki Bazarbashi, Ahmed Badran, et al. – World Journal of Surgical Oncology, 2020.

PMID: 32641137 | DOI: 10.1186/s12957–020–01930–8

Empirical monetary valuation of a quality-adjusted life-year in the Kingdom of Saudi Arabia: a willingness-to-pay analysis. Edward B De Vol, Shouki Bazarbashi, Fatma Maraiki, et al. – PharmacoEconomics – Open, 2020.

PMID: 32291726 | DOI: 10.1007/s41669–020–00211–0

Efficacy and prognostic factors of sunitinib as first-line therapy for patients with metastatic renal cell carcinoma in an Arab population. Ahmed Badran, Shouki Bazarbashi, Mahmoud A Elshenawy, et al. – JCO Global Oncology, 2020.

PMID: 32031432 | DOI: 10.1200/JGO.19.00111

The significance of sidedness in patients with metastatic colorectal cancer treated with triplet first-line chemotherapy. Ayman T Omar, Shouki Bazarbashi, Leen Raddaoui, et al. – Asian Pacific Journal of Cancer Prevention, 2019.

PMID: 31653131

Trends and patterns of primary hepatic carcinoma in Saudi Arabia. Fazal Hussain, Shouki Bazarbashi, Njoud Alrshoud, et al. – Gulf Journal of Oncology, 2019.

PMID: 31591990

Organizing pneumonia secondary to cetuximab in a patient with colorectal cancer. Abdulaziz AlGhulayqah, Shouki Bazarbashi, Bader AlShamsan, et al. – Monaldi Archives for Chest Disease, 2019.

PMID: 31508927

Efficacy of second-line chemotherapy after a first-line triplet in patients with metastatic colorectal cancer. A M Hakoun, Shouki Bazarbashi, M A Elshenawy, et al. – Current Oncology, 2019.

PMID: 30853806

Efficacy of regorafenib in metastatic colorectal cancer: a multi-institutional retrospective study. Ali Aljubran, Shouki Bazarbashi, Magdy Kandil, et al. – Clinical Medicine Insights: oncology, 2019.

PMID: 30728734

Spectrum of the KIT gene mutations in gastrointestinal stromal tumors in Arab patients. Muhammad Faiyaz–Ul–Haque, Shouki Bazarbashi, Asma Tulba, et al. – Asian Pacific Journal of Cancer Prevention, 2018.

PMID: 30362320 

Utilization and cost of electronic resources in adult cancer center. Fatma Maraiki, Shouki Bazarbashi, Mohamed Ahmed, et al. – BMC Research Notes, 2018.

PMID: 30055654

Dose escalation with Simultaneous Integrated Boost (SIB) using Volumetric Modulated Arc Therapy (VMAT) in rectal cancer. Abdullah Alsuhaibani, Shouki Bazarbashi, Rana Mahmood, et al. – Journal of Gastrointestinal Cancer, 2018.

PMID: 30006679

Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for prostate cancer 2017. Ali Aljubran, Shouki Bazarbashi, Ashraf Abusamra, et al. – Urology Annals, 2018.

PMID: 29719323

Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder 2017. Sultan Alkhateeb, Shouki Bazarbashi, Mubarak Al–Mansour, et al. – Urology Annals, 2016.

PMID: 27141179

Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma 2017. Abdullah Alsharm, Shouki Bazarbashi, Mohammed AlOtaibi, et al. – Urology Annals, 2018.

PMID: 29719321 | DOI: 10.4103/UA.UA_175_17

Patient and oncologist perceptions regarding symptoms and impact on quality-of-life of oral mucositis in cancer treatment: results from the Awareness Drives Oral Mucositis PercepTion (ADOPT) study. Jeevendra Kanagalingam, Shouki Bazarbashi, Mohamed Ibrahim A Wahid, et al. – Supportive Care in Cancer, 2018.

PMID: 29387994 | DOI: 10.1007/s00520–018–4050–3

Cancer incidence in Saudi Arabia: 2012 data from the Saudi cancer registry. Haya Al Eid, Shouki Bazarbashi, Joan Minguet – Asian Pacific Journal of Cancer Prevention, 2017.

PMID: 28952273 | DOI: 10.22034/APJCP.2017.18.9.2437

Pre-operative chemoradiotherapy using capecitabine and cetuximab followed by definitive surgery in patients with operable rectal cancer. Ayman Omar, Shouki Bazarbashi, Ali Aljubran, et al. – Hematology/Oncology and Stem Cell Therapy, 2016.

PMID: 27613373 | DOI: 10.1016/j.hemonc.2016.08.004

Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical bacillus Calmette–Guerin: a single center experience and analysis of prognostic factors. Haya J Azouz, Shouki N Bazarbashi,Mohammed F Alotaibi, et al. – Urology Annals, 2016.

PMID: 27453656 | DOI: 10.4103/0974–7796.184891

Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for testicular germ cell tumors. Ahmad Saadeddin, Shouki Bazarbashi, Mohammed Alotaibi, et al. – Urology Annals, 2016.

PMID: 27141181 | DOI: 10.4103/0974–7796.179240

Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma. Abdullah Alghamdi, Shouki Bazarbashi, Sultan Alkhateeb, et al. – Urology Annals, 2016.

PMID: 27141180 | DOI: 10.4103/0974–7796.179239

Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for prostate cancer. Ashraf Abusamra, Shouki Bazarbashi, Hussain Kushi, et al. – Urology Annals. 2016

PMID: 27141178 | DOI: 10.4103/0974–7796.176872

Adjuvant chemotherapy for rectal cancer: time to change the guidelines. Ali Aljubran, Shouki Bazarbashi, Ahmad Alzahrani – Future Oncology, 2016.

PMID: 26863297 | DOI: 10.2217/fon–2015–0042

Colorectal cancer in Saudi Arabia: incidence, survival, demographics and implications for national policies. Nasser Alsanea, Shouki Bazarbashi, Samar Alhomoud, et al. – Annals of Saudi Medicine, 2015.

PMID: 26409793 | DOI: 10.5144/0256–4947.2015.196

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer. Ali Aljubran, Shouki Bazarbashi, Ahmad Alzahrani, et al. – Cancer Medicine, 2015.

PMID: 26207614 | DOI: 10.1002/cam4.497

Awareness and perceptions of clinical trials in cancer patients and their families in Saudi Arabia. Anees Hassan, Shouki Bazarbashi, Ahmed Mohi Eldin, et al. – Journal of Cancer Education, 2016.

PMID: 25663358 | DOI: 10.1007/s13187–015–0797–0

Saudi Oncology Society clinical management guideline series. Esophageal cancer 2014. Ali M Alzahrani, Shouki N Bazarbashi, Mohammed M Rahal, et al. – Saudi Medical Journal, 2014.

PMID: 25491227

Saudi Oncology Society clinical management guideline series. Colorectal cancer 2014. Ali M Alzahrani, Shouki N Bazarbashi, Mohammed M Rahal, et al. – Saudi Medical Journal, 2014

PMID: 25491226

Saudi Oncology Society clinical management guideline series. Pancreatic cancer 2014. Mohammed M Rahal, Shouki N Bazarbashi, Magdy S Kandil, et al. – Saudi Medical Journal, 2014.

PMID: 25491225

Saudi Oncology Society clinical management guideline series. Gastric cancer 2014. Magdy S Kandil, Shouki N Bazarbashi, Mohammed M Rahal, et al. – Saudi Medical Journal, 2014.

PMID: 25491224

Saudi oncology society and Saudi urology association combined clinical management guidelines for urothelial urinary bladder cancer. Mubarak Al–Mansour, Shouki Bazarbashi, Sultan Alkhateeb, et al. – Urology Annals, 2014.

PMID: 25371600 | DOI: 10.4103/0974–7796.140941

Metastatic castration resistant prostate cancer: current strategies of management in the Middle East. Shouki Bazarbashi, Mohammed AlOtaibi, Marwan Bachour – Critical Reviews in Oncology/Hematology, 2014.

PMID: 24289901 | DOI: 10.1016/j.critrevonc.2013.11.001

Seminoma presenting as a polypoid bladder mass: report of a case. Akhtar M, Shouki Bazarbashi, Alotaibi M. F. – Turkish Journal of Pathology, 2013.

PMID: 24272936 | DOI: 10.5146/tjpath.2013.01201

Incidence of thyroid cancer in the Kingdom of Saudi Arabia, 2000–2010. Fazal Hussain, Shouki Bazarbashi, Asif Mehmood, et al. – Hematology/Oncology and Stem Cell Therapy, 2013.

PMID: 23756719 | DOI: 10.1016/j.hemonc.2013.05.004

Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ayman A Abdo, Mazen Hassanain, AbdulRahman AlJumah, et al. – Annals of Saudi Medicine, 2012.

PMID: 22366832 | DOI: 10.5144/0256–4947.2012.174

Saudi Oncology Society clinical management guidelines for urinary bladder cancer. Khaled Al Othman, Shouki Bazarbashi, Mohamed Al Otaibi, et al. – Urology Annals, 2011.

PMID: 21673850 | DOI: 10.4103/0974–7796.78549

Saudi Oncology Society clinical management guidelines for renal cell carcinoma. Khaled Al Othman, Shouki Bazarbashi, Mohammed Al Otaibi, et al. Urology Annals, 2011.

PMID: 21673849 | DOI: 10.4103/0974–7796.78548

Saudi Oncology Society clinical management guidelines for prostate cancer. Elnaghi M, Shouki Bazarbashi, Balaraj K, et al. – Urology Annals, Supplement, 2011.

PMID: 21673847 | DOI: 10.4103/0974–7796.78550

Co–administration of intravesical bacillus Calmette–Guérin and interferon α–2B as first line in treating superficial transitional cell carcinoma of the urinary bladder. Hussein Soudy, Shouki Bazarbashi, Mahmoud Abdelsalam, et al. – BJU International, 2011.

PMID: 21332904 | DOI: 10.1111/j.1464–410X.2010.10040.x

Whole body 18F–FDG PET predicts progression free and overall survival in squamous cell carcinoma of the esophagus: results of a prospective trial. Mahmoud Abdelsalam, Shouki Bazarbashi, Moheieldin Abouzied, et al. – Hematology/Oncology and Stem Cell Therapy, 2010.

PMID: 21150237 | DOI: 10.5144/1658–3876.2010.179

Extraskeletal Ewing's sarcoma family of tumours in adults: analysis of 57 patients from a single institution. A El Weshi, Shouki Bazarbashi, F Al Dayel, et al. - Clinical Oncology (Royal College of Radiologists), 2010.

PMID: 20466282 | DOI: 10.1016/j.clon.2010.02.010

Phase II trial of neoadjuvant cisplatin, 5-fluorouracil and interferon-alpha in operable squamous cell carcinoma of the esophagus. Mahmoud Abdelsalam, Shouki Bazarbashi, Tarek Amin, et al. – Chemotherapy, 2008.

PMID: 18701820 | DOI: 10.1159/000151353

A modern regimen of pre-operative concurrent chemo-radiation therapy in locally advanced rectal cancer. Shouki Bazarbashi 1, Mazen El–Bassiouni, Mahmoud Abdelsalam, et al. – Journal of Surgical Oncology.

PMID: 18615536 | DOI: 10.1002/jso.21097 /p>

T–cell/histiocyte-rich B-cell lymphoma: clinical presentation, management and prognostic factors: report on 61 patients and review of literature. Amr El Weshi, Shouki Bazarbashi, Saad Akhtar, et al. Leukemia & Lymphoma, 2007.

PMID: 17786712 | DOI: 10.1080/10428190701559124

Immature teratoma of the thyroid gland: a case report and review of the literature. S Al–Sobhi, S Bazarbashi, B Al–Jiffry, et al. – Annals of Saudi Medicine, 1998.

PMID: 17341980 | DOI: 10.5144/0256–4947.1998.254

The incidence of lung cancer in the Gulf Cooperation Council countries. Nasser Al-Hamdan, Shouki Bazarbashi, Mohammed Al–Jarallah, et al. – Annals of Saudi Medicine, 2006.

PMID: 17143018 | DOI: 10.5144/0256–4947.2006.433

VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors. Amr El Weshi, Shouki Bazarbashi, Madras Raja, et al. – American Journal of Clinical Oncology, 2004.

PMID: 15596925 | DOI: 10.1097/01.coc.0000135815.94162.83

Phase II trial of cisplatin, 5–fluorouracil, and interferon–alpha–2B as first line treatment of advanced urothelial cancer. Chandrashaker Pai, Shouki Bazarbashi, Madras A Raja, et al. – Urologic Oncology: Seminars and Original Investigations, 2003.

PMID: 12810204 | DOI: 10.1016/s1078–1439(02)00204–1

Appraisal of communication skills and patients' satisfaction in cross-language encounters in oncology practice. Ezzeldin M Ibrahim, Shouki Bazarbashi, Amr L Wishi, Yasser M Khafaga, et al. – Journal of Cancer Education (JCE), 2002.

PMID: 12556059 | DOI: 10.1080/08858190209528841

A pilot trial of combination cisplatin, 5–fluorouracil and interferon–alpha in the treatment of advanced esophageal carcinoma. Mohammed Rahal, Shouki Bazarbashi, Madras A Raja, et al. – Chemotherapy, 2002.

PMID: 12218269 | DOI: 10.1159/000063870

Localized non-Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients. A A Ezzat, Shouki Bazarbashi, A N El Weshi, et al. – Head Neck, 2001.

PMID: 11400243 | DOI: 10.1002/hed.1077

The correlation of Epstein-Barr virus expression and lymphocyte subsets with the clinical presentation of nodular sclerosing Hodgkin disease. A Kandil, S Bazarbashi, W A Mourad – Cancer, 2001.

PMID: 11391573 | DOI: 10.1002/1097–0142(20010601)91:11<1957::aid–cncr1220>3.0.co;2–6

Positron emission tomography in Hodgkin's disease. Correlation with computed tomography and Gallium 67 citrate imaging. A Rifai A, S Bazarbashi, A Kandil – Clinical Positron Imaging, 2000.

PMID: 11150782 | DOI: 10.1016/s1095–0397(00)00091–1

High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin. A A Ezzat, Shouki Bazarbashi, D S Ajarim, et al. – Breast Cancer Research and Treatment, 2000.

PMID: 11072788 | DOI: 10.1023/a:1006434406989

Prospective phase II trial of alternating intravesical Bacillus Calmette–Guérin (BCG) and interferon alpha IIB in the treatment and prevention of superficial transitional cell carcinoma of the urinary bladder: preliminary results. M A Raja, S Bazarbashi, A El Sayed, et al. – Journal of Surgical Oncology, 2000.

PMID: 10951412 | DOI: 10.1002/1096–9098(200007)74:3<181::aid–jso3>3.0.co;2–f

Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non–Hodgkin's lymphoma: an interim analysis of a randomized phase III trial. A A Ezzat 1, Shouki Bazarbashi, R K Stuart, et al. – Medical Oncology, 2000.

PMID: 10713659 | DOI: 10.1007/BF02826215

Primary gastric non–Hodgkin's lymphoma: clinical features, management, and prognosis of 185 patients with diffuse large B–cell lymphoma. E M Ibrahim, Shouki Bazarbashi, A A Ezzat, et al. – Annals of Oncology, 1999.

PMID: 10643534 | DOI: 10.1023/a:1008325823967

Metastatic transitional cell carcinoma of the ovary from superficial bladder tumor. A H Kardar, Shouki Bazarbashi, A M Tulbah, et al. – Scandinavian Journal of Urology and Nephrology, 1998.

PMID: 9561583 | DOI: 10.1080/003655998750014774

The lack of age as a significant prognostic factor in non–metastatic breast cancer. A Ezzat, Shouki Bazarbashi, M Brigden, et al. – European Journal of Surgical Ontology 1998.

PMID: 9542511 | DOI: 10.1016/s0748–7983(98)80120–0

An overview of breast cancer. A Ezzat, Shouki Bazarbashi, A Rostom, et al. – Annals of Saudi Medicine, 1997.

PMID: 17377456 | DOI: 10.5144/0256–4947.1997.10

Frequency and distribution of 22,836 adult cancer cases referred to King Faisal Specialist Hospital and Research Centre. A Ezzat 1, Shouki Bazarbashi, O Te, et al. – Annals of Saudi Medicine, 1996.

PMID: 17372420

Impact of pregnancy on non–metastatic breast cancer: a case control study. A Ezzat 1, Shouki Bazarbashi, J Berry, et al. – Clinical Oncology (Royal College of Radiologists), 1996.

PMID: 8973852 | DOI: 10.1016/s0936–6555(96)80081–1

Ki–1 large cell lymphoma: a clinical study of 12 cases. A A Ezzat, Shouki Bazarbashi, M Akhtar, et al. – Annals of Saudi Medicine, 1995.

PMID: 17587894 | DOI: 10.5144/0256–4947.1995.25

Malignant cystosarcoma phyllodes: a review of the clinical experience at King Faisal Specialist Hospital and Research Centre. A Ezzat, Shouki Bazarbashi, M El–Senoussi, et al. – Annals of Saudi Medicine, 1994.

PMID: 17586891 | DOI: 10.5144/0256–4947.1994.198

ORCID:Shouki Bazarbashi (0000–0002–8913–8158)

Real-world outcomes of nivolumab plus ipilimumab vs immune checkpoint inhibitor and tyrosine kinase inhibitor combinations for metastatic clear cell renal cell carcinoma. Faisal Azam, Bassam Mohammed Basulaiman, Mohamed Aseafan, et al. – Journal of Clinical Oncology, 2025.

DOI: 10.1200/JCO.2025.43.16_suppl.e16510

A multi-centre study comparing granulocyte–colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia. Mark Clemons, Bassam Basulaiman, Dean Fergusson, et al. – Breast, 2021.

PMID: 33901921 | DOI: 10.1016/j.breast.2021.03.012

Mortality and morbidity of curative and palliative anticancer treatments during the COVID–19 pandemic: A multicenter population–based retrospective study. Emad Tashkandi, Bassam Basulaiman, Amal Al-Abdulwahab, et al. – Molecular Clinical Oncology, 2021.

PMID: 33758663 | DOI:10.3892/mco.2021.2244

The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized–controlled trials. Francesco G.T. Fazzari, Bassam Basulaiman, Foster Rose, et al. – Critical Reviews in Oncology/Hematology, 2022.

PMID: 34808376 | DOI: 10.1016/j.critrevonc.2021.103540

Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. Terry L Ng, Bassam Basulaiman, Megan M Tu, et al. – Support Care Cancer, 2021.

PMID: 32535678 | DOI: 10.1007/s00520-020-05556-0

Oral magnesium supplements for cancer treatment‐induced hypomagnesemia: Results from a pilot randomized trial. Arif Awan, Bassam Basulaiman, Carol Stober, et al. – Health Science Reports, 2021.

PMID: 34938893 | DOI: 10.1002/hsr2.

A prospective multi-centre, randomized study comparing the addition of tapering dexamethasone to other standard of care therapies for taxane–associated pain syndrome (TAPS) in breast cancer patients. Mark Clemons, Bassam Basulaiman, Demetrios Simos, et al – Supportive Care in Cancer, 2021.

PMID: 33742240 | DOI: 10.1007/s00520–021–06142–8

A randomized trial comparing vascular access strategies for patients receiving chemotherapy with trastuzumab for early–stage breast cancer. Mark Clemons, Bassam Basulaiman, Carol Stober, et al. – Supportive Care in Cancer, 2020.

PMID: 32002617 | DOI: 10.1007/s00520–020–05326–y

Thirty-day mortality after curative and palliative anti-cancer treatment: data interpretation and lessons for clinical implementation. Emad Tashkandi, Bassam Basulaiman, Waleed Alghareeb, et al. – Cancer Management & Research, 2020.

PMID: 33293858 | DOI: 10.2147/CMAR.S277924

A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non–trastuzumab containing chemotherapy. Andrew Robinson, Bassam Basulaiman, Carol Stober, et al. – Breast Cancer Research & Treatment, 2019.

PMID: 31392518 | DOI: 10.1007/s10549–019–05388–5

Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT). Arif Ali Awan, Bassam Basulaiman, Dean Fergusson, et al. – Breast Cancer Research & Treatment, 2019.

PMID: 31127468 | DOI: 10.1007/s10549–019–05274–0

Conflict of interest: "Be rigorous in judging ourselves and gracious in judging others". Arif Ali Awan, Bassam Basulaiman, J F Hilton, et al. – Current Oncology, 2018.

PMID: 30607108 | DOI: 10.3747/co.25.4587

Fibroblast growth factor receptor 3 mutation as a prognostic indicator in patients with urothelial carcinoma: a systematic review and meta-analysis. Sidra Khalid, Bassam Basulaiman, Jeffrey Emack, et al. – European Urology Open Science, 2021.

PMID: 34337469 | DOI: 10.1016/j.euros.2020.08.008

Management of early and metastatic breast cancer: a consensus statement from oncologists in Saudi Arabia. Sabah Alaklabi, Bassam Basulaiman, Sadal Al Refaei, et al. – Oncology and Therapy, 2025.

PMID: 41261349 | DOI: 10.1007/s40487–025–00404–9

Efficacy and toxicity of extending bone modifying agents beyond two years for bone metastases in breast or castrate-resistant prostate cancer patients: a systematic review. Terry L Ng, Bassam Basulaiman, Megan M Tu, et al. – Journal of Clinical Oncology, 2020.

DOI: 10.1200/JCO.2020.38.15_suppl.e24083

360P Real–world treatment and clinical outcomes in metastatic castration–resistant prostate cancer (mCRPC): REMPRO-Middle East and Africa (MEA). Gaber El Husseiny, Bassam Basulaiman, Amr Nowier, et al. – Annals of Oncology, 2024.

DOI: 10.1016/j.annonc.2024.10.379

P3. 01–04 Immune checkpoint inhibitors (ICIs) in NSCLC: immune related adverse events (irAEs) and outcomes. a Canadian single institution experience. K Virik, Bassam Basulaiman, A Robinson, W Hopman, et al. – Journal of Thoracic Oncology, 2018.

DOI: 10.1016/j.jtho.2018.08.1564

A multicenter study comparing granulocyte–colony stimulating factors to antibiotics for primary prophylaxis of taxotere/cyclophosphamide–induced febrile neutropenia in patients with early–stage breast cancer. Mark J. Clemons, Bassam Basulaiman, Dean Fergusson, et al. – J Clin Oncol, 2020.

PMID: 33901921 | DOI: 10.1200/JCO.2020.38.15_suppl.7001

205P – A prospective, multicentre, randomized trial comparing vascular access strategies for patients receiving non–trastuzumab containing chemotherapy for early–stage breast cancer. AA Awan, B Basulaiman, A Robinson, et al. – Annals of Oncology, 2019.

DOI: 10.1093/annonc/mdz101.006

211P – A cost–utility analysis of administration schedules of G–CSF for primary prophylaxis of chemotherapy–induced febrile neutropenia in early–stage breast cancer: Economic evaluation alongside the REaCT–G trial A.A. Awan, B. Basulaiman, J. Hilton, et al. – Annals of Oncology, 2019.

DOI: 10.1093/annonc/mdz101.012

Impact of the time to initiation in patients with glioblastoma. Abdullah AlHumiqani, Bassam Basulaiman, Ashraf Elyamany, et al.- Journal of Integrative Oncology, 2018.

DOI: 10.4172/2329–6771.1000209

Impact of the time to initiation of chemoradiation on outcome of glioblastoma. A Al Alhumiqani, Bassam Basulaiman, AK Altwairgi, et al. – Annals of Oncology, 2017.

DOI: 10.1093/annonc/mdx657.006 External Link

ORCID: Bassam M.Basulaiman (0000–0002–0088–6038)

Malignant idiopathic intracranial hypertension revealed a hidden primary spinal leptomeningeal medulloblastoma. Naim Izet Kajtazi, Ali Al Fakeeh, Shahpar Nahrir, et al. – British Medical Journal Case Rep, 2021.

PMID: 34321265 | DOI: 10.1136/bcr–2021–243506

Investigating the prevalence of pathogenic variants in Saudi Arabian patients with familial cancer using a multigene next generation sequencing panel. Musa AlHarbi, Ali H AlFakeeh, Nahla Ali Mobark, et al. – Oncotarget, 2023.

PMID: 37306523 | DOI: 10.18632/oncotarget.28457

Real-world clinical outcome of unresectable locally advanced & de–novo metastatic pancreatic ductal adenocarcinoma: a multicenter retrospective study. Mohamed Aseafan, Ali H Alfakeeh, Emad Tashkandi, et al. – BioMed Central Cancer, 2025.

PMID: 39754118 | DOI: 10.1186/s12885–024–13386–0

Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports. Ali Al Zahrani, Ali Alfakeeh – Journal of Medical Case Reports, 2021

PMID: 33722275 | DOI: 10.1186/s13256–021–02695–8

Overcoming endocrine resistance in hormone receptor–positive breast cancer. A AlFakeeh, C Brezden–Masley – Current Oncology, 2018.

PMID: 29910644 | DOI: 10.3747/co.25.3752

Quality of reporting of chemotherapy compliance in randomized controlled trials of "breast cancer treatment Abdullah K Altwairgi", Ali H Alfakeeh, Wilma M Hopman, et al. – Japanese Journal of Clinical Oncology, 2015.

PMID: 26059696 | DOI: 10.1093/jjco/hyv043

A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma. Lorenzo Ferri, Ali H Alfakeeh, Nasser Mulla, et al. – Medical Oncology 2016.

PMID: 27225939 | DOI: 10.1007/s12032–016–0774–4

Venous Thromboembolism in Patients with Sarcoma: A Retrospective Study. Thierry Alcindor, Ali Al–Fakeeh, Krista Goulding, et al. – The Oncologist 2018.

PMID: 30257890 | DOI: 10.1634/theoncologist.2018–0081

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. D Bossé , Ali Al–Fakeeh, T Ng 1 et al. – ECGCCC, 2016.

PMID: 28050151 | DOI: 10.3747/co.23.3394

An educational program about premarital screening for unmarried female students in King Abdul–Aziz University, Jeddah. Nahla Khamis Ragab Ibrahim, Ali Al–Fakeeh, Hussein Al–Bar, et al. – Journal of Infection and Public Health, 2011.

PMID: 21338957 | DOI: 10.1016/j.jiph.2010.11.001

Knowledge, attitudes, and practices relating to Dengue fever among females in Jeddah high schools. Nahla Khamis Ragab Ibrahim, Ali Al–Fakeeh, Adnan Al–Bar, et al. – Journal of Infection and Public Health, 2009

PMID: 20701858 | DOI: 10.1016/j.jiph.2009.01.004

ORCID: Ali Alfakeeh (0000–0001–9574–8940)

Phase II trial of FOLFIRINOX in advanced biliary tract cancer. Shouki Bazarbashi, Mohammed Aseafan, Mahmoud A., et al. – Cureus, 2024.

PMID: 38380191 | DOI: 10.7759/cureus.52656

Prognostic significance of peritoneal metastasis from colorectal cancer treated with first–line triplet chemotherapy. Shouki Bazarbashi, Mohammed Aseafan, Abdulrahman Alghabban, et al. – World Journal of Clinical Cases, 2022.

PMID: 35434075 | DOI: 10.12998/wjcc.v10.i8.2429

Management of metastatic colorectal cancer: Consensus in the Gulf cooperation council countries. Shouki Bazarbashi, Mohammed Aseafan, Abdelsalam Alnajjar, et al. – Therapeutic Advances in Medical Oncology, 2025.

PMID: 39759829 | DOI: 10.1177/17588359241299324

Real-world clinical outcome of unresectable locally advanced and de–novo metastatic pancreatic ductal adenocarcinoma: a multicenter retrospective study. AH Alfakeeh , Mohammed Aseafan, E Tashkandi, et al. – BMC Cancer, 2025.

PMID: 39754118 | DOI: 10.1186/s12885–024–13386–0

Prognostic significance of the neutrophil to lymphocyte ratio in locally advanced breast cancer. B Alshamsan, Mohammed Aseafan, MA Elshenawy, et al. – Oncology Letters, 2024.

PMID: 39049989 | DOI: 10.3892/ol.2024.14562

Thyroid abscess in a young postpartum female. Sultan Almdallaleh, Mohamed Aseafan, Latif Khan – Cureus Journal of Medical Science, 2022.

PMID: 36381905 | DOI: 10.7759/cureus.30082

Thromboembolic events burden in patients with solid tumors and their predisposing factors. Shouki Bazarbashi, Mohamed Aseafan, Turkiah Alkhaldi, et al. – Cureus Journal of Medical Science, 2022.

PMID: 35386484 | DOI: 10.7759/cureus.23624

Outcomes and prognostic factors of metastatic gastric cancer: a single-center experience. Ahmed Mostafa Gad, Mohamed Aseafan, Bader Alshamsan, et al. – Cureus Journal of Medical Science, 2022.

PMID: 36043200 | DOI: 10.7759/cureus.28426

Pazopanib as treatment option for pseudomyogenic hemangioendothelioma: a case report. Ali Alhanash, Mohamed Aseafan, Jean Atallah – Cureus Journal of Medical Science, 2022.

PMID: 35755544 | DOI: 10.7759/cureus.25250

Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care center. Shouki Bazarbashi, Mohamed Aseafan, Tasnim Elgazzar, et al. – BMC Endocrine Disorders, 2023.

PMID: 37029347 | DOI: 10.1186/s12902–023–01326–1

Characteristics and outcomes of small bowel adenocarcinoma: 14 years of experience at a single tertiary hospital in Saudi Arabia. Bader Alshamsan, Mohamed Aseafan, Ahmed Badran, et al. – Molecular and Clinical Oncology, 2023.

PMID: 36798464 | DOI: 10.3892/mco.2023.2613

Population–based survival for cancer patients in Saudi Arabia for the years 2005–2009. Edward Devol, Mohamed Aseafan, Mahmoud AlAhwal, et al. – Scientific Reports, 2024.

PMID: 34997176 | DOI: 10.1038/s41598–021–04374–6

Outcomes of patients with metastatic colorectal cancer treated with trifluridine/tipiracil beyond the second line: a multicenter retrospective study from Saudi Arabia. Mohammed Alghamdi, Mohamed Aseafan, Shouki Bazarbashi, et al. – Journal of Oncology, 2022.

PMID: 36147443 | DOI: 10.1155/2022/3796783

Outcomes of autologous stem cell transplantation in patients with primary refractory diffuse large B-cell lymphoma who demonstrate chemosensitivity to salvage chemotherapy. M Shahzad Rauf, Mohamed Aseafan, Irfan Maghfoor, et al. – Clinical Hematology International, 2024.

PMID: 38817310 | DOI: 10.46989/001c.115919

Efficacy of chemotherapy rechallenge versus regorafenib or trifluridine/tipiracil in third line setting of metastatic colorectal cancer: a multicenter retrospective comparative study. Shouki Bazarbashi, Mohamed Aseafan, Radwan Alkhatib, et al. – JCO Global Oncology, 2024.

PMID: 38484194 | DOI: 10.1200/GO.23.00461

Nationwide prevalence of hepatocellular carcinoma in Saudi Arabia: a population-based analysis for 2021 Edward B De Vol, Mohamed Aseafan, Shouki Bazarbashi, et al. – Journal of Hepatocellular Carcinoma, 2025.

PMID: 41487559 | DOI: 10.2147/JHC.S576090

Treatment outcome and chemoresistance-related factors of low-risk gestational trophoblastic neoplasia: results from a tertiary care center in Saudi Arabia. Bader Alshamsan, Mohamed Aseafan, Inaam Ahmed Ibrahim, et al. – JCO Global Oncology, 2025.

PMID: 41397193 | DOI: 10.1200/GO–25–00172

Docetaxel versus androgen receptor pathway inhibitors as first-line therapy for metastatic castration-resistant prostate cancer after doublet therapy: a multicenter retrospective study from Saudi Arabia. Shouki Bazarbashi, Mohamed Aseafan, Ahmed S Abdelmotal, et al. – BMC Urology, 2025.

PMID: 41430171 | DOI: 10.1186/s12894–025–02019–8

Adjuvant abemaciclib‑induced pneumonitis: a case report and review of the literature. Abdulrahman Al‑Ghabban, Mohamed Aseafan, Aisha Al‑Shibany, et al. – World Academy of Sciences Journal, 2021.

DOI:10.3892/wasj.2021.99

Patient's characteristics and outcome of small bowel adenocarcinoma in Saudi Arabia. Bader I Alshamsan, Mohamed Aseafan, Ahmed Ali Badran, et al. – Molecular and Clinical Oncology, 2021.

PMID: 36798464 | DOI: 10.3892/mco.2023.2613

Efficacy and safety of second–line lenvatinib after progression on immunotherapy in advanced hepatocellular carcinoma: A systematic review and meta–analysis. Tarek Arabi, Mohamed Aseafan, Abdullah Alruwaili, et al. – Journal of Clinical Oncology, 2025.

DOI: 10.1200/JCO.2025.43.16_suppl.e16258

Real–world outcomes of nivolumab plus ipilimumab vs immune checkpoint inhibitor and tyrosine kinase inhibitor combinations for metastatic clear cell renal cell carcinoma. Faisal Azam, Mohamed Aseafan, Bassam Mohammed Basulaiman, et al. – Journal of Clinical Oncology, 2025.

DOI: 10.1200/JCO.2025.43.16_suppl.e16510

464P Enhancing management of localized gastric cancer: the added value of prophylactic HIPEC and IORT to conventional surgery. M Shouki Ahmad, Mohamed Aseafan, A Bazarbashi, et al. – Annals of Oncology, 2024.

DOI: 10.1016/j.annonc.2024.05.376

P–210 Efficacy and tolerability of cetuximab 750 mg/m2 every three weeks in metastatic colorectal cancer Kanan Alshammari, Mohamed Aseafan, Bader Alshamsan, et al. – Annals of Oncology, 2023.

DOI: 10.1016/j.annonc.2023.04.266

P-332 Characteristic and clinical outcome of localized gastric cancer; real-world data. A AlJuhani, M Aseafan, A Sheikh, et al. – Annals of Oncology, 2023.

DOI: 10.1016/j.annonc.2023.04.388 

Efficacy and prognostic significance of triflurodine/tipiracil beyond oxaliplatin and irinotecan-based chemotherapy in patients with refractory metastatic colorectal cancer: an observational multicenter study. Mohamed Alghamdi, Mohamed Aseafan, Shouki Bazarbashi, et al. – Journal of Clinical Oncology, 2021.

DOI: 10.1200/JCO.2021.39.15_suppl.e15586

264P Neutrophil–to–lymphocyte ratio as a prognostic factor for neoadjuvant chemotherapy for locally advanced breast cancer. B Alshamsan, MJ Aseafan, N Fahmy, et al. – Annals of Oncology, 2023.

DOI: 110.1016/j.annonc.2020.08.073

ORCID: Mohamed Aseafan (0000–0001–9993–9664)

Romidepsin treatment in patients with relapsed or refractory peripheral T–cell lymphoma: A systematic review and meta-analysis. Waleed Abdulsattar, Ali Alqahtani, Azizullah Beran, et al. – American Journal of Therapeutics, 2021.

PMID: 34264886 | DOI: 10.1097/MJT.0000000000001419

Prognostic utility of preoperative and postoperative circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Abdulrahma Alloghbi, Ali Alqahtani, Chao Yin, et al. – Gastrointestinal Cancers Symposium, 2022.

PMID: 37852124 | DOI: 10.1016/j.suronc.2023.102007

Use of circulating tumor DNA to assess minimal residual disease in gastrointestinal cancers. Reetu Mukherji, Ali Alqahtani, Harrison D. Winters, et al. – touchREVIEWS in Oncology and Haematology, 2022.

DOI: 10.17925/OHR.2022.18.1.26

Current state of targeted therapy and immunotherapy in advanced gastric and gastroesophageal cancers. Chao Yin, Ali Alqahtani, John L. Marshall, et al. – touchREVIEWS in Oncology and Haematology, 2022.

DOI: 10.17925/OHR.2022.18.1.16

The next frontier in pancreatic cancer: targeting the tumor immune milieu and molecular pathways. Chao Yin, Ali Alqahtani, Marcus S. Noel, et al. – Cancers, 2022.

PMID: 35681599 | DOI: 10.3390/cancers14112619

Microwave-assisted N,S doped carbon quantum dots as fluorescent nanoprobes for vibegron determination: face-centered design optimization, validation, and green chemistry assessment. Humood Al Shmrany, Ali Alqahtani, Taha Alqahtani, et al.– RSC Advances, 2026.

PMID: 41710490 | DOI: 10.1039/d5ra08942e

Perioperative therapy landscape for locally advanced, resectable esophageal cancer: an updated literature review. Reetu Mukherji, Ali Alqahtani, Chao Yin, et al. – Journal of Thoracic Disease (JTD), 2023.

PMID: 37426147 | DOI: 10.21037/jtd–23–27

Overcoming the hurdles: surmounting acquired resistance to anti-EGFR therapy in metastatic colorectal cancer Paul E Sackstein, Ali Alqahtani, Nikita Chintapally, et al. – Advances in Hematology, 2023.

PMID: 37948593

Real-world Monitoring of ctDNA reliably predicts cancer recurrence and treatment efficacy in patients with resected stages I–III colon cancer. Stacey A Cohen, Ali Alqahtani, Vasily N Aushev, et al. – Annals of Surgery, 2025.

PMID: 40772634 | DOI: 10.1097/SLA.0000000000006887

Biological properties, bioactive constituents, and pharmacokinetics of some capsicum spp. and capsaicinoids. Gaber El–Saber Batiha, Ali Alqahtani, Oluwafemi Adeleke, et al. – International journal of molecular sciences 2020.

PMID: 32707790 | DOI: 10.3390/ijms21155179

Hepatocellular carcinoma: molecular mechanisms and targeted therapies. Zubair Khan, Ali Alqahtani, Abdurahman Alloghbi, et al. – Medicina 2019.

PMID: 31450841 | DOI: 10.3390/medicina55090526

Bromodomain and extra–terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Khalil Choucair, Ali Alqahtani, Mushtaq Ashraf et al. – Future science OA, 2019.

PMID: 30906568

Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Sherif A Gaballa, Ali Alqahtani, Uday B Kompella, et al.– Drug Delivery and Translational Research, 2021.

PMID: 32901367 | DOI: 10.1007/s13346–020–00843–z

Avermectin derivatives, pharmacokinetics, therapeutic and toxic dosages, mechanism of action, and their biological effects. Gaber El–Saber Batiha, Ali Alqahtani, Omotayo B Ilesanmi, et al. – Pharmaceuticals, 2020.

PMID: 32824399 | DOI: 10.3390/ph13080196

Techno-economic design and evaluation of hybrid energy systems for residential communities: case study of jubail industrial city. MA Baseer, Ali Alqahtani, S Rehman, et al. – Journal of Cleaner Production, 2019.

DOI: 10.1016/j.jclepro.2019.117806

Novel lignin nanoparticles for oral drug delivery. Mohammed S Alqahtani, Ali Alqahtani, Abdullah Al–Thabit, et al. – Journal of Materials Chemistry B, 2019.

DOI: 10.1039/C9TB00594C

Deep time–series clustering: a review. Mohammed Ali, Ali Alqahtani, Xianghua Xie, et al. – Electronics, 2021.

DOI: 10.3390/electronics10233001

Pectin co–functionalized dual layered solid lipid nanoparticle made by soluble curcumin for the targeted potential treatment of colorectal cancer. J. Muthu Mohamed, Ali Alqahtani, Fazil Ahmad, et al. – Carbohydrate Polymers, 2021.

DOI: 10.1016/j.carbpol.2020.117180

Wound–healing potential of curcumin loaded lignin nanoparticles. Mohammed S Alqahtani, Ali Alqahtani, Mohsin Kazi, et al. – Journal of Drug Delivery Science and Technology, 2020.

DOI: 10.1016/j.jddst.2020.102020

Clustering and classification for time series data in visual analytics: A survey. Mohammed Ali, Ali Alqahtani, Mark W Jones, et al. – IEEE Access, 2019.

DOI: 10.1109/ACCESS.2019.2958551

Trastuzumab deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review. Ziad Abuhelwa, Ali Alqahtani, Abdurahman Alloghbi, et al. – Drugs, 2022.

PMID: 35759121| DOI: 10.1007/s40265–022–01736–w

Numerical modeling and analysis of bioconvection on MHD flow due to an upper paraboloid surface of revolution. Mair Khan, Ali Alqahtani, T Salahuddin, et al. – Physica A: Statistical Mechanics and its Applications, 2020.

DOI: 10.1016/j.physa.2020.124231

Guided tissue and bone regeneration membranes: a review of biomaterials and techniques for periodontal treatments. Robert Moorehead, Ali Alqahtani, Ilida Ortega Asencio, et al. – Polymers, 2023.

PMID: 37631412 | DOI: 10.3390/polym15163355

PIK3CA gene mutations in solid malignancies: association with clinicopathological parameters and prognosis. Hazem SK Ayesh, Ali Alqahtani, Hafez Halawani – Cancers, 2019.

PMID: 31905960 | DOI: 10.3390/cancers12010093

Current status of CRISPR/Cas9 application in clinical cancer research: opportunities and challenges. Rafii S, Bukhari N, Tashkandi E, et al. – Cancers (Basel), 2022.

PMID: 35205694 | DOI: 10.3390/cancers14040947

Navigated transcranial magnetic stimulation-based preoperative planning for brain tumor treatment. Riaz H, Bukhari N, Uzair M, et al. – CNS Neurological Disorders – Drug Targets, 2024.

PMID: 37340739 | DOI: 10.2174/1871527322666230619103429

Treatment outcomes of gestational trophoblastic disease: experience from Saudi Arabia. Latif MF, Bukhari N, Azam F, et al. – Journal of Ayub Medical College Abbottabad, 2024.

PMID: 39609967 | DOI: 10.55519/JAMC–02–12695

Eligibility criteria for different platinum-based chemotherapy regimens in metastatic urothelial carcinoma. Azam F, Bukhari N, Alharbi H, et al. – Cureus, 2024.

PMID: 39246966 | DOI: 10.7759/cureus.66520

Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals. Faisal Azam, Nedal Bukhari, Muhammad Farooq Latif, et al. – Case reports in oncology, 2020.

PMID: 31616281 | DOI: 10.1159/000503095

Update on the treatment of metastatic urothelial carcinoma. Humaid O Al–Shamsi, Nedal Bukhari, Faisal Azam – Scientific World Journal, 2018.

PMID: 29977169 | DOI: 10.1155/2018/5682078c

Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients. Wendy A Teft, Nedal Bukhari, Eric Winquist, et al. – Oral Oncology, 2019.

PMID: 30732962 | DOI: 10.1016/j.oraloncology.2018.12.010

Early stage anaplastic sarcomatoid carcinoma of the pancreas, a case report. Amani Joudeh, Nedal Bukhari – The American Journal of Case Reports, 2019.

PMID: 31023997

Identifying a Novel DPYD Polymorphism Associated with Severe Toxicity to 5‐FU Chemotherapy in a Saudi Patient. Faisal Azam, Nedal Bukhari, Mohammed Alfawaz, et al. – Case Reports in Genetics, 2019.

PMID: 31531249 | DOI: 10.1155/2019/5150725

Case: secondary polycythemia due to pazopanib in patients with metastatic renal cell carcinoma. Eric Winquist, Nedal Bukhari – Canadian Urological Association Journal, 2017.

PMID: 29072563 | DOI: 10.5489/cuaj.4519

Fluoropyrimidine-induced severe toxicities associated with rare DPYD polymorphisms: case series from Saudi Arabia and a review of the literature. Abdulraheem Alshangiti, Nedal Bukhari, Emad Tashkandi, et al. – Clinics and Practice, 2021.

PMID: 34449540

Malignant anaplastic meningioma in neurofibromatosis type 1 patient: a rare case report. Ghada A AlAnsari, Nedal Bukhari, Marwah M Abdulkader, et al. – AME case reports, 2022.

PMID: 36339910 | DOI: 10.21037/acr–22–8

Impact of COVID–19 pandemic on psychological wellbeing of Oncology clinicians in the Middle East and North Africa (MENA) region. Faisal Azam, Nedal Bukhari, MF Latif, et al. – European Review for Medical & Pharmacological Sciences, 2022.

PMID: 35179772 | DOI: 10.26355/eurrev_202202_28015

Immediate response to chemotherapy in an adult neuroblastoma patient presenting with cord compression. Bachar Harfouch, Nedal Bukhari, Majid Shallal Alotaibi, et al. – Case Reports in Neurological Medicine, 2020.

PMID: 32148983

Metastatic cecal adenocarcinoma to the gallbladder presenting with acute cholecystitis. Nedal Bukhari, Marwah Abdulkader – Case reports in oncological medicine, 2018.

PMID: 30420930 | DOI: 10.1155/2018/5308585

Real-world clinical outcome of unresectable locally advanced and de–novo metastatic pancreatic ductal adenocarcinoma: a multicenter retrospective study. Mohamed Aseafan, Nedal Bukhari, Emad Tashkandi, et al. – BioMed Central Cancer, 2025.

PMID: 39754118 | DOI: 10.1186/s12885–024–13386–0

Primary intracranial solitary fibrous tumor with metachronous pulmonary and bone metastasis: a case report. Haila Alabssi, Mohamed Aseafan, Maram Alismail, et al. – Cureus, 2022.

PMID: 36654576 | DOI: 10.7759/cureus.32607

Exceptional response to second–line gemcitabine/nab–paclitaxel chemotherapy in patients with metastatic pancreatic adenocarcinoma. Khalda Abdalla, Nedal Bukhari, Fahad Ibnshamsa et al. – Cureus, 2022.

PMID: 34796055 | DOI: 10.7759/cureus.18756

Suggested modifications to the management of patients with breast cancer during the COVID–19 pandemic: web-based survey study. Shereef Elsamany, Nedal Bukhari, Mohamed Elbaiomy, et al. – JMIR cancer, 2021.

PMID: 34726611 | DOI : 10.2196/27073

Awareness, understanding, attitude and barriers toward prescribing modern cancer immunotherapies in the Arabian Gulf countries. Humaid O Al–Shamsi, Nedal Bukhari, Emad Tashkandi et al. – Gulf J Oncolog, 2018. 

PMID: 30145551

Navigated transcranial magnetic stimulation (nTMS) based preoperative planning for brain tumor treatment. Hammad Riaz, Nedal Bukhari, Mohammad Uzair, et al. – CNS and Neurological Disorders-Drug Targets-CNS & Neurological Disorders), 2024.

PMID: 37340739 | DOI: 10.2174/1871527322666230619103429

Influence of aggressive–variant prostate cancer (AVPC) features on outcome of metastatic hormone–sensitive prostate cancer (mHSPC) treated by chemohormonal therapy (CHT). Kim Koczka, Nedal Bukhari, James Vanhie, et al. – Journal of Clinical Oncology, 2018.

DOI: 10.1200/JCO.2018.36.6_suppl.193

Chronic oxaliplatin-based chemotherapy in a primary ampullary adenocarcinoma patient without significant peripheral neuropathy: case report and literature review. Nedal Bukhari, Eric Winquist – Case Reports in Oncology, 2017.

PMID: 28868015| DOI: 10.1159/000477841

Thymidylate synthase (TYMS) and methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms associated with severe capecitabine toxicity: the first case from Saudi Arabia. Hani Al–Mohanna, Nedal Bukhari, Fahad Almsned, et al. – Cureus, 2023.

PMID: 38143640 | DOI: 10.7759/cureus.49215

Metastatic type II papillary renal cell carcinoma with recurrent complete responses to sunitinib: a case report with a literature review. Bayan H Al Ashour, Nedal Bukhari, Faisal Azam, et al. – Cureus, 2022.

PMID: 35800817 | DOI: 10.7759/cureus.25541

Sunitinib: an unusual cause of pneumothorax in a patient with metastatic chromophobe renal cell carcinoma. Suha Al–Badr, Nedal Bukhari, Manal AlNaimi, et al. – Cureus, 2020.

PMID: 32923192 | DOI: 10.7759/cureus.9586

Histological patterns and clinical characteristics of metastatic gastric adenocarcinoma, single institutional experience in the eastern province of Saudi Arabia. Wiam Taha, Nedal Bukhari, Amer Zahralliyali, et al.- Annals of Oncology, 2019.

DOI: 10.1093/annonc/mdz155.235 External Link

Efficacy of neoadjuvant short-course radiation therapy followed by oxaliplatin-based chemotherapy for locally advanced rectal adenocarcinoma: a single-center experience from Saudi Arabia. Tareq Salah, Nedal Bukhari, Mohamed Aboziada, et al. – Cureus, 2025.

PMID: 39963619 | DOI: 10.7759/cureus.77604

Eligibility criteria for different platinum-based chemotherapy regimens in metastatic urothelial carcinoma. Faisal Azam, Nedal Bukhari, Hulayel Alharbi, et al. – Cureus, 2024.

PMID: 39246966 | DOI: 10.7759/cureus.66520

P–254 Outcomes and prognostic factors of resected pancreatic ductal adenocarcinoma in Saudi Arabia. K Alshammari, Nedal Bukhari, A Samman, et al. – Annals of Oncology, 2023.

DOI: 10.1016/j.annonc.2023.04.310

Case report Immediate response to chemotherapy in an adult neuroblastoma patient presenting with cord compression. Bachar Harfouch, Nedal Bukhari, Majid Shallal Alotaibi, et al. – Hindawi, 2020.

DOI: 10.1155/2020/6401497

Is bleomycin safe in management of primary mediastinal germ cell tumor? Single cancer center experience at Saudi Arabia. W Alselwi, N Bukhari, F Azam, et al. Lung Cancer, 2020.

DOI: 10.1016/S0169–5002(20)30198–7

EP1133 Duration of chemotherapy for normalization of BHCG and treatment outcomes of gestational trophoblastic neoplasia at a tertiary cancer center in Saudi Arabia. Faisal Azam, N Bukhari, Waleed Al–Selwi, et al. – International Journal of Gynecological Cancer, 2019.

DOI: 10.1136/ijgc-2019-ESGO.1175

Do Royal Marsden Hospital (RMH) and MD Anderson Cancer Center (MDACC) prognostic scoring systems predict survival in patients with bone sarcoma? W Alselwi, N Bukhari, F Azam, et al. – Annals of Oncology, 2018.

DOI: 10.1093/annonc/mdy299.035

The effect of MATE1 polymorphisms on cisplatin efficacy in patients with head and neck cancer. Daniel Adam Breadner, Nedal Bukhari, Mary Mahler – Journal of Clinical Oncology, 2018.

DOI: 10.1200/JCO.2018.36.15_suppl.e18069

Early docetaxel–resistance in metastatic hormone–sensitive prostate cancer. Kylea R Potvin, Nedal Bukhari, D Scott Ernst, et al. – Journal of Clinical Oncology, 2017.

DOI: 10.1200/JCO.2017.35.6_suppl.260

Nonalcoholic steatohepatitis with significantly elevated levels of carbohydrate antigen 19–9. Nedal Ahmed Bukhari, Stephen Welch – Scholars Middle East Publishers, 2017.

DOI: 10.36348/sjmps.2017.v03i01.004

Pharmacogenomic predictors of cisplatin oto–and nephrotoxicity in head and neck cancer patients treated with chemoradiation. E Winquist, N Bukhari,WA Teft, et al. – Annals of Oncology, 2016.

DOI: 10.1093/annonc/mdw376.33

ORCID: Nedal Bukhari (0000–0002–6166–5490)

Outcomes of patients with hematological malignancies admitted to the ICU at a tertiary care center in Saudi Arabia. Yazeed Alekrish, Ghazi Saud Alotaibi, Fares Aldokhayel, et al. – Saudi Journal of Medicine & Medical Sciences, 2025.

PMID: 3993599 | DOI: 10.4103/sjmms.sjmms_257_24

Guidelines on management of multiple myeloma in the relapsed/refractory setting: the Saudi Myeloma Working Group guideline. Ayman Alhejazi, Ghazi S Alotaibi, Abdullah S Al Saleh, et al. – Clinical Lymphoma, Myeloma & Leukemia, 2025.

PMID: 40483258 | DOI: 10.1016/j.clml.2025.05.005

Definition, diagnosis, risk stratification, and management of newly diagnosed multiple myeloma: the Saudi Myeloma Working Group guidelines. Abdullah S Al Saleh, Ghazi S Alotaibi, Ayman Alhejazi, et al. – Clinical Lymphoma, Myeloma & Leukemia, 2025.

PMID: 40617770 | DOI: 10.1016/j.clml.2025.06.005

The clinical conundrum of managing ischemic stroke in patients with immune thrombocytopenia. Alrohimi A, AlOtaibi G, Purdy K, et al. – Canadian Journal of Neurological Sciences, 2021.

PMID: 32646527 | DOI: 10.1017/cjn.2020.138

Saudi experts statement on advancing multiple myeloma treatment: the evolving role of bispecific antibodies. Ahmad Alsaeed, Ghazi S Alotaibi, Majed Alahmadi, et al. – Frontiers in Medicine, 2026.

PMID: 41647027 | DOI: 10.3389/fmed.2025.1730261

Interventions in primary care to improve cervical cancer screening: a systematic review. Anas E Ahmed, Ghazi S Alotaibi, Wasan M Hatan, et al. – Cureus, 2025.

PMID: 41556025 | DOI: 10.7759/cureus.99604

Correction: the safety and efficacy of low-molecular-weight heparin in pregnant women with rheumatic heart disease and valves replacement. Najwa Alghamdi, Ghazi S Alotaibi, Saeed Alqahtani, et al. – Cureus. 2025.

PMID: 41113872 | DOI: 10.7759/cureus.c366

Osteosarcoma metastasis to the thorax: a pictorial review of chest computed tomography findings. Khalid Abdulaziz Alduraibi, Ghazi S Alotaibi, Jawaher Ali Towhari, et al. – Diagnostics, 2024.

PMID: 39335763 | DOI: 10.3390/diagnostics14182085

Multiple myeloma: A personal account of my journey with the disease and response to teclistamab. Mohammad Ahmad, Ghazi S Alotaibi, Musa F Zahrani, et al. – Cureus, 2024.

PMID: 38846238 | DOI: 10.7759/cureus.59781

Response to lisinopril in patients with sickle cell anemia and proteinuria. Aamer Aleem, Ghazi S Alotaibi, Abdulrahman Al–Sultan, et al. – Saudi Journal of Kidney Diseases and Transplantation, 2023.

PMID: 38725203 | DOI: 10.4103/sjkdt.sjkdt_312_22

Homozygous missense variant F12 (Gly506Asp) associated with severe factor XII deficiency: a case report. Mansour Aljabry, Ghazi S Alotaibi, Aljoud Algazlan, et al. – Journal of Medical Case Reports and Reviews, 2023

PMID: 38057855 | DOI: 10.1186/s13256–023–04238–9

A young patient with undiagnosed polycythemia-paraganglioma syndrome: a case report. Abdulaziz Mohammed Alaklabi, Ghazi S Alotaibi, Tarek Ziad Arabi, et al. – American Journal of Case Reports, 2023.

PMID: 37160900 | DOI: 10.12659/AJCR.938676

Secular trends in incidence and mortality of acute venous thromboembolism: the AB-VTE population-based study. Cynthia Wu, Ghazi S Alotaibi, Ambikaipakan Senthilselvan, et al. – The American Journal of Medicine, 2016.

PMID: 26925811 | DOI: 10.1016/j.amjmed.2016.01.041

Role of extended thromboprophylaxis after abdominal and pelvic surgery in cancer patients: a systematic review and meta-analysis. Andrei Fagarasanu, Ghazi S Alotaibi, Ramona Hrimiuc, et al. – Annals of Surgical Oncology, 2016.

PMID: 26887853 | DOI: 10.1245/s10434–016–5127–1

The validity of ICD codes coupled with imaging procedure codes for identifying acute venous thromboembolism using administrative data. Cynthia Wu, Ghazi S Alotaibi, Ambikaipakan Senthilselvan, et al. – Vascular Medicine, 2015.

PMID: 25834115 | DOI: 10.1177/1358863X15573839

Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention. Cynthia Wu, Ghazi S Alotaibi, Khalid Alsaleh, et al. – Thrombosis Research, 2014.

PMID: 25488466 | DOI: 10.1016/j.thromres.2014.10.033

Case fatality of bleeding and recurrent venous thromboembolism during initial therapy with direct oral anticoagulants: a systematic review. Cynthia Wu, Ghazi S Alotaibi, Khalid Alsaleh, et al. – Thrombosis Research, 2014.

PMID: 25047174 | DOI: 10.1016/j.thromres.2014.07.001

Preoperative transfusion in patients with sickle cell disease to prevent perioperative complications: a systematic review and meta-analysis. Khalid Alsaleh, Ghazi S Alotaibi, Lauren Bolster, et al. – Hematology, 2014.

PMID: 24611757 | DOI: 10.1179/1607845414Y.0000000158

Do women bleed more than men when prescribed novel oral anticoagulants for venous thromboembolism? A sex–based meta–analysis. Hind Almodaimegh, Ghazi S Alotaibi, M Sean McMurtry, et al. – Thrombosis Research, 2013.

PMID: 23932014 | DOI: 10.1016/j.thromres.2013.07.017

The use of preoperative erythropoiesis–stimulating agents (ESAs) in patients who underwent knee or hip arthroplasty: a meta–analysis of randomized clinical trials. Khalid Alsaleh, Ghazi S Alotaibi, Hind S Almodaimegh, et al. – The Journal of Arthroplasty, 2013.

PMID: 23528548 | DOI: 10.1016/j.arth.2013.01.024

ORCID: Ghazi AlOtaibi (0000–0002–6902–1876)

The comprehensive cancer center: development, integration, and implementation. Al Hayli S, Hussain F, Aljurf M, et al. – Springer, 2022.

PMID: 36121970 | DOI: 10.1007/978–3–030–82052–7

Duodenal-type follicular lymphoma: comprehensive insights into disease characteristics and established treatment strategies. Alnughmush A, Al Hayli S, Fakih R.E., et al. – Current Opinion in Oncology, 2024.

PMID: 39246163 | DOI: 10.1097/CCO.0000000000001093

Minimal residual disease testing for diffuse large B-cell lymphoma. Atout M, Al Hayli S, Elwaheidi H., et al. – Clinical Lymphoma, Myeloma & Leukemia, 2025.

PMID: 40447539 | DOI: 10.1016/j.clml.2025.05.003

Incidence and significance of donor–specific antibodies in haploidentical stem cell transplantation. Altareb M, Al Hayli S, Al–Awwami M, et al. – Bone Marrow Transplantation, 2023.

PMID: 36959370 | DOI: 10.1038/s41409–023–01950–4

Programmed death inhibitors in CNS B–cell lymphoma: a literature review Mostafa Mohammed Saleh, Al Hayli S, Walid Rasheed, et al. – Blood Reviews, 2025.

PMID: 40695648 | DOI: 10.1016/j.blre.2025.101321

Data unit, translational research, and registries Fazal Hussain, Saud Alhayli, Mahmoud Aljurf, et al. – Comprehensive Cancer Center: Development, Integration, and Implementation, 2022.

PMID: 36122092 | DOI: 10.1007/978–3–030–82052–7_16

Uncommon entities, uncommon challenges: a review of rare plasma cell disorders Amr Hanbali , Al Hayli S, Abdullah Alamer, et al. – Hematology Reports, 2025.

PMID:40700098 | DOI:10.3390/hematolrep17040031

Guidelines on management of multiple myeloma in the relapsed/refractory setting: the Saudi myeloma working group guideline. Ayman Alhejazi, Al Hayli S, Abdullah S Al Saleh, et al. – Clinical Lymphoma, Myeloma & Leukemia, 2025.

PMID: 40483258 | DOI: 10.1016/j.clml.2025.05.005

Definition, diagnosis, risk stratification and management of newly diagnosed multiple myeloma: the Saudi myeloma working group guidelines. Abdullah S Al Saleh, Al Hayli S, Ayman Alhejazi – Clinical Lymphoma, Myeloma & Leukemia, 2025.

PMID: 40617770 | DOI: 10.1016/j.clml.2025.06.005

Improved survival of adolescents and young adults’ patients with T–cell acute lymphoblastic leukemia. Amr Hanbali, Al Hayli S, Ahmed Kotb, et al. – International Journal of Hematologic Oncology, 2023.

PMID: 36874377 | DOI: 10.2217/ijh–2022–0005

Outcomes of adolescent and young adult (AYA) patients with relapsed/refractory B–cell acute lymphoblastic leukemia treated with tisagenlecleucel, real world evidence from the middle east. Amr Hanbali, Al Hayli S, Fahad Bahkali, et al. – Cytotherapy, 2025.

PMID: 40767822 | DOI: 10.1016/j.jcyt.2025.07.006

Myeloablative haploidentical donor hematopoietic transplantation using post–transplantation cyclophosphamide and antithymocyte globulin. Riad El Fakih, Al Hayli S, Momen Nassani, et al. – Transplantation and Cellular Therapy, 2024.

PMID: 38185379 | DOI: 10.1016/j.jtct.2024.01.054

Frontline-matched sibling donor transplant of aplastic anemia patients using primed versus steady-state bone marrow grafts. Riad El Fakih, Al Hayli S, Feras Alfraih, et al. – Annals of Hematology, 2022.

PMID: 34719735 | DOI: 10.1007/s00277–021–04708–4

Successful restoration of checkpoint inhibitors efficacy after allogeneic hematopoietic cell transplant for classic Hodgkin lymphoma patients. Riad El Fakih, Al Hayli S, Abdulwahab A Albabtain, et al. – Seminars in Oncology, 2023.

PMID: 37598020 | DOI: 10.1053/j.seminoncol.2023.05.001

Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia. Ahmed Kotb Abdrabou, Al Hayli S, Riad El Fakih, et al. – Annals of Saudi Medicine, 2021.

PMID: 34420396 | DOI: 10.5144/0256–4947.2021.198

Allogeneic transplant compared to pediatric-inspired therapy for Philadelphia chromosome-negative adolescent and adult all in first complete remission. Alfadil Haroon, Al Hayli S, Feras Alfraih, et al. – Nature, 2022.

PMID: 35110691 | DOI: 10.1038/s41409–022–01595–9

Incidence and risk factors for secondary graft failure in uniformly treated patients with severe aplastic anemia receiving fludarabine and cyclophosphamide for conditioning and matched sibling bone marrow graft as stem cell source. Ahmed Kotb, Al Hayli S, Hazzaa Alzahrani, et al. – Cytotherapy, 2023.

PMID: 37737766 | DOI: 10.1016/j.jcyt.2023.08.009

Outcomes of allogeneic hematopoietic cell transplant for acute myeloid leukemia in adolescent patients. Riad El Fakih, Al Hayli S, Ahmed Kotb, et al. – Nature, 2020.

PMID: 31488877 | DOI: 10.1038/s41409–019–0667–1

Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients. Ahmed Kotb Abdrabou, Al Hayli S, Fahad Al Sharif, et al. – Annals of Saudi Medicine, 2023.

PMID: 38615184 | DOI: 10.5144/0256–4947.2024.93

Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. Igor Novitzky-Basso, Saud AlHayli, Elizabeth Shin, et al. – European Journal of Haematology, 2021.

PMID: 33421199 | DOI: 10.1111/ejh.13576

Full dose cyclophosphamide with the addition of fludarabine for Matched Sibling Transplants in Severe Aplastic Anemia. Riad El Fakih, Saud Alhayli, Syed Osman Ahmed, et al. – Transplantation and Cellular Therapy, 2021.

PMID: 34126277 | DOI: 10.1016/j.jtct.2021.06.004

Clinical course and outcomes of COVID–19 in hematopoietic cell transplant patients, a regional report from the Middle East. Riad El Fakih, Al Hayli S, Alfadil Haroon, et al. – Bone Marrow Transplantation, 2021.

PMID: 33907304 | DOI: 10.1038/s41409–021–01312–y

The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor-risk cytogenetic abnormalities. Mona Hassanein, Al Hayli S, Riad El Fakih, et al. – EJHaem, 2021.

PMID: 35845278 | DOI: 10.1002/jha2.136

Improved survival in adolescents and young adults (AYA) patients aged 14–55 years with acute lymphoblastic leukemia using pediatric-inspired protocol – a retrospective analysis of a real–world experience in 79 of patients treated at a national tertiary care referral center. Amr Hanbali, Al Hayli S, Ahmed Kotb, et al. – Leukemia Research Reports, 2021.

PMID: 34631407 | DOI: 10.1016/j.lrr.2021.100270

Outcomes of adolescent LBCL patients treated with adult type chemotherapy: a single center experience. Riad El Fakih, Al Hayli S, Taimoor Hussain, et al. – Clinical Lymphoma, Myeloma & Leukemia, 2025.

PMID: 40222877 | DOI: 10.1016/j.clml.2025.03.009

Improved outcome of a pediatric-inspired protocol for high-risk adolescent and young adult acute Lymphoblastic leukemia patients using peg-asparaginase and escalating dose of methotrexate: tolerability and outcome. Amr Hanbali, Al Hayli S, Ahmed Kotb, et al. – Clinical Lymphoma, Myeloma & Leukemia, 2019.

PMID: 31377206 | DOI: 10.1016/j.clml.2019.05.004

Outcome of hematopoietic stem cell transplantation (HCT) from HLA-matched related donor for Fanconi Anemia (FA) in adolescents and adults: a retrospective study by Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT). Ghuzayel AlDawsari, Al Hayli S, Alaa Elhaddad, et al. – Nature, 2020.

PMID: 32024988 | DOI: 10.1038/s41409–020–0809–5

Outcomes of human leukocyte antigen matched sibling transplant from consanguineous versus non-consanguineous parents, a single center experience. Riad El Fakih, Al Hayli S, Mohamed I Sharif , et al. – Nature, 2025.

PMID: 40301662 | DOI: 10.1038/s41409–025–02609–y

Transplant outcomes in adolescents and young adults with Philadelphia–positive B–cell acute lymphoblastic leukaemia. Manar Aleid, Al Hayli S, Riad El Fakih, et al. – British Journal of Haematology, 2026.

PMID: 41582435 | DOI: 10.1111/bjh.70347

Prognostic factors and real-world outcomes in Adolescents and Young Adults (AYA) with Philadelphia-negative Acute Lymphoblastic Leukemia (ALL) treated with the AYA-15 protocol: a retrospective cohort study from a tertiary care referral center in the Middle East. Amr Hanbali, Al Hayli S, Ayman Saad, et al. – Clinical Lymphoma Myeloma and Leukemia, 2025.

PMID: 40769787 | DOI: 10.1016/j.clml.2025.07.006

Saudi experts statement on advancing multiple myeloma treatment: the evolving role of bispecific antibodies. Ahmad Alsaeed, Al Hayli S, Majed Alahmadi, et al. – Frontiers in Medicine, 2026.

PMID: 41647027 | DOI: 10.3389/fmed.2025.1730261

Utility and implementation of the distress thermometer for cancer patients: a cross-sectional study from Saudi Arabia. Mohammed Alghamdi, Fadi Masharqa, Abdulrahman Alsultan et al. – Cureus, 2024.

PMID: 38681302 | DOI: 10.7759/cureus.57187

Renal metastases from thyroid cancer masquerading as renal angiomyolipoma on ultrasonography. Ahmed M, Ahmad J, Aslam M, et al. – Journal of Ultrasound in Medicine, 2006.

PMID: 17060435 | DOI: 10.7863/jum.2006.25.11.1459

Rare soft tissue tumors and tumor-like lesions: radiologic–pathologic correlation. Al–Ismail K, Ahmad J, Al–Shaalan M, et al. – Poster presented at AMS, AGSSR Meeting, 2010.

Radiofrequency thermal ablation of osteoid osteoma: the good, bad, and ugly. Al–Ismail K, Ahmad J, Al–Shaalan M, et al. – Presentation at International Skeletal Society (ISS) Scientific Meeting, 2010.

Outcome on non–metastatic osteosarcoma in patients age 14 and above: single institution experience. Memon MA, Ahmad J – Journal of Clinical Oncology, 2008.

Miyoshi myopathy in Saudi Arabia. Edward J Cuplera, Ahmad J, Saeed Bohlega, et al. – Neuromuscular Disorders, 1998.

PMID: 9673986 | DOI: 10.1016/s0960–8966(98)00026–1

Mri vs ct of the lateral parapharyngeal space: influence upon surgical treatment. K.M. Dupuch, Ahmad J, et al- Diagnostic and Interventional Radiology, 1988.

Case Presentation: Aneurysmal bone cyst (abc) is not as easy as abc. Ahmad J., Khalid Almane, et al - 8th International MRI Conference & 1st Saudi Radiology Conference, 2002.

Imaging of liver transplantation complications. Hussain F., Ahmad J., et al. - E-medicine (Medscape), 2010.

Determining the correlation between comorbidities and MERS-CoV mortality in Saudi Arabia. Alotaibi MH, Bahammam SA – Journal of Taibah University Medical Sciences, 2021.

PMID: 33727906 | DOI: 10.1016/j.jtumed.2021.02.003

Gender differences in patients with obesity hypoventilation syndrome. Pandi-Perumal SR, Bahammam SA, Piper A, et al. – Journal of Sleep Research, 2016.

PMID: 26990045 | DOI: 10.1111/jsr.12400

The influence of intermittent fasting on the circadian pattern of melatonin while controlling for caloric intake, energy expenditure, light exposure, and sleep schedules: a preliminary report. Almeneessier AS, Bahammam SA, Sharif MM, et al. – Annals of Thoracic Medicine, 2017.

PMID: 28808490 | DOI: 10.4103/atm.ATM_15_17

Prevalence of thyroid disease in patients with obstructive sleep apnea. Sharif MM, Bahammam SA, Jammah AA. – Respiratory Medicine, 2011.

PMID: 21820299 | DOI: 10.1016/j.rmed.2011.07.007

Circadian pattern of sleep, energy expenditure, and body temperature of young healthy men during the intermittent fasting of Ramadan. Ahmed BaHammam, Bahammam SA, Mohammad Alrajeh, et al. – Appetite 2010

PMID: 20100529 | DOI: 10.1016/j.appet.2010.01.011

A comparison between the AASM 2012 and 2007 definitions for detecting hypopnea. Ahmed S BaHammam, Bahammam SA, Amr Obeidat, et al.

PMID: 24493077 | DOI: 10.1007/s11325–014–0939–3

Sleep medicine education and knowledge among medical students in selected Saudi medical schools. Abdulellah Almohaya, Bahammam SA, Abdulaziz Qrmli, et al. – BMC Medical Education, 2013.

PMID: 24070217 | DOI: 10.1186/1472–6920–13–133

The demographic and clinical characteristics of leprosy in Saudi Arabia. Mohammad H Alotaibi, Salman A Bahammam, Saeed ur Rahman, et al. – Journal of Infection and Public Health, 2016.

PMID: 26810580 | DOI: 10.1016/j.jiph.2015.12.015

Predictors of long-term outcomes of radiologically defined perianal fistulizing crohn’s disease treated with antitumor necrosis factor–alpha agents based on parks’ classification. Nahla Azzam, Bahammam SA, Othman Alharb, et al. – European Journal of Gastroenterology & Hepatology, 2020.

PMID: 31851087 | DOI: 10.1097/MEG.0000000000001634

Attitudes and behaviors of physicians towards the relationship with the pharmaceutical industry in Saudi Arabia. Suhail Asiri, Salman Bahammam, Yassar Al–Jahdali, et al. – Eastern Mediterranean Health Journal, 2020.

PMID: 32281642 | DOI: 10.26719/emhj.19.024

P567 Long–term outcome of perianal fistulae treated with anti–TNFα therapy in a cohort of Saudi patients with Crohn’s disease based on Parks classification. N Azzam, O Alharbi, Bahammam SA, A Aljebreen, et al. – Journal of Crohn's and Colitis, 2018.

ORCID:Salman A.Bahammam(0000–0001–9129–0370)